Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Intellia Therapeutics (NTLA) Misses Q4 EPS by 9c, Revenues Miss
February 25, 2021 7:39 AM ESTIntellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.69), $0.09 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $14.09 million.
Intellias achievements in 2020 reflect important progress on both our full-spectrum strategy and our mission to deliver... More
